NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LXEO

Lexeo Therapeutics Inc

Jul 01 • 04:00PM ET

4.22

Dollar change +0.20
Percentage change 4.98	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP QURE SRPT NTLA BEAM RARE BLUE EDIT SGMO ADVM

| Held by: IWM VTI VXF IWN IBB VTWO IWC DFAT RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.31	Insider Own	31.02%	Shs Outstand	33.19M	Perf Week	0.24%
Market Cap	140.09M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	-0.12%	Shs Float	22.90M	Perf Month	55.15%
Enterprise Value	49.66M	PEG	-	EPS next Q	-0.67	Inst Own	90.35%	Short Float	20.89%	Perf Quarter	21.61%
Income	-109.31M	P/S	-	EPS this Y	14.56%	Inst Trans	16.21%	Short Ratio	5.23	Perf Half Y	-37.76%
Sales	0.00M	P/B	1.59	EPS next Y	23.50%	ROA	-64.51%	Short Interest	4.78M	Perf YTD	-35.87%
Book/sh	2.65	P/C	1.40	EPS next 5Y	18.09%	ROE	-80.65%	52W High	19.50 -78.36%	Perf Year	-71.60%
Cash/sh	3.01	P/FCF	-	EPS past 3/5Y	-17.65% -99.98%	ROIC	-115.22%	52W Low	1.45 191.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.14% 11.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-28.80%	Oper. Margin	-	ATR (14)	0.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.83	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	3.42	EPS Q/Q	-27.27%	SMA20	6.18%	Beta	1.32	Target Price	17.71
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	19.05%	Rel Volume	0.73	Prev Close	4.02
Employees	72	LT Debt/Eq	0.08	Earnings	May 12 BMO	SMA200	-23.39%	Avg Volume	914.68K	Price	4.22
IPO	Nov 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.39% -	Trades		Volume	663,290	Change	4.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-13-24	Initiated	Robert W. Baird	Outperform	$28
Jun-06-24	Initiated	H.C. Wainwright	Buy	$22
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

Jun-24-25 07:30AM	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics (GlobeNewswire) +6.31%
May-27-25 07:31AM	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases (GlobeNewswire)
May-12-25 07:00AM	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
May-05-25 02:19PM	Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (Seeking Alpha)
May-01-25 09:16AM	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) +19.85%
06:00AM	Loading…
Apr-07-25 06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study (GlobeNewswire) -23.34%
Mar-25-25 09:10AM	Pharma Frenzy: Volatility Ignites Biotech Sector (MarketBeat) +8.56%
08:44AM	Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? (Insider Monkey)
Mar-24-25 07:00AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (GlobeNewswire) +50.92%
Jan-07-25 07:30AM	Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 07:00AM	Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer (GlobeNewswire) -5.03%
Dec-02-24 07:00AM	Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 (Business Wire)
Nov-13-24 07:30AM	Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 06:14AM	Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) -17.00%
Oct-22-24 07:30AM	Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference (GlobeNewswire)
07:30AM	Loading…
Sep-05-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Jul-16-24 11:03AM	Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data (Zacks)
Jul-15-24 04:17PM	Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion (Investor's Business Daily) -26.08%
10:11AM	Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout (Investor's Business Daily)
06:36AM	Lexeo gene therapy shows signs of heart benefit in small study (BioPharma Dive)
06:00AM	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire)
Jul-11-24 08:00AM	Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 (GlobeNewswire) +6.08%
Jul-08-24 07:00AM	Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors (GlobeNewswire) +5.55%
May-14-24 12:00PM	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet (Zacks)
May-09-24 07:00AM	Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +5.69%
May-07-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
04:22PM	Loading…
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67% -5.43%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Townsend Richard Nolan	Chief Executive Officer	May 16 '25	Sale	2.77	1,074	2,979	221,173	May 20 05:00 PM
Adler Eric	Chief Medical Officer	May 16 '25	Sale	2.77	585	1,623	67,681	May 20 05:00 PM
Robertson Jenny	Chief Legal Officer	May 16 '25	Sale	2.77	521	1,445	63,098	May 20 05:00 PM
See Tai Sandi	Chief Development Officer	May 16 '25	Sale	2.77	367	1,018	59,242	May 20 05:00 PM
Townsend Richard Nolan	Officer	May 16 '25	Proposed Sale	2.77	1,074	2,980		May 16 03:51 PM
Robertson Jenny	Officer	May 16 '25	Proposed Sale	2.77	521	1,445		May 16 03:41 PM
See Tai Sandi	Officer	May 16 '25	Proposed Sale	2.77	367	1,018		May 16 03:36 PM
Adler Eric	Officer	May 16 '25	Proposed Sale	2.77	585	1,623		May 16 03:35 PM
Townsend Richard Nolan	Chief Executive Officer	Feb 19 '25	Sale	4.41	4,326	19,091	220,119	Feb 21 05:10 PM
See Tai Sandi	Chief Development Officer	Feb 19 '25	Sale	4.41	1,486	6,558	53,889	Feb 21 05:09 PM
Adler Eric	Chief Medical Officer	Feb 19 '25	Sale	4.41	2,359	10,410	68,266	Feb 21 05:09 PM
Robertson Jenny	Chief Legal Officer	Feb 19 '25	Sale	4.41	2,101	9,272	57,899	Feb 21 05:08 PM
Townsend Richard Nolan	Officer	Feb 19 '25	Proposed Sale	4.41	4,326	19,091		Feb 19 04:25 PM
Robertson Jenny	Officer	Feb 19 '25	Proposed Sale	4.41	2,101	9,272		Feb 19 04:19 PM
See Tai Sandi	Officer	Feb 19 '25	Proposed Sale	4.41	1,486	6,558		Feb 19 04:15 PM
Adler Eric	Officer	Feb 19 '25	Proposed Sale	4.41	2,359	10,410		Feb 19 04:06 PM
Townsend Richard Nolan	Chief Executive Officer	Dec 10 '24	Option Exercise	2.33	2,500	5,825	123,195	Dec 12 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	Dec 10 '24	Sale	8.20	2,500	20,491	120,695	Dec 12 05:00 PM
Richard Nolan Townsend	Director	Dec 10 '24	Proposed Sale	8.24	2,500	20,600		Dec 10 05:18 PM
CHOLMONDELEY PAULA H	Director	Nov 25 '24	Buy	6.99	15,000	104,852	30,627	Nov 26 05:00 PM
Townsend Richard Nolan	Chief Executive Officer	Nov 11 '24	Option Exercise	2.33	2,500	5,825	123,195	Nov 13 05:33 PM
Townsend Richard Nolan	Chief Executive Officer	Nov 11 '24	Sale	7.82	2,500	19,557	120,695	Nov 13 05:33 PM
Townsend Richard Nolan	Chief Executive Officer	Oct 10 '24	Option Exercise	2.33	5,000	11,650	125,695	Oct 15 01:45 PM
Townsend Richard Nolan	Chief Executive Officer	Oct 10 '24	Sale	8.10	5,000	40,496	120,695	Oct 15 01:45 PM
Townsend Richard Nolan	Chief Executive Officer	Sep 10 '24	Option Exercise	2.33	5,000	11,650	125,695	Sep 11 05:17 PM
Townsend Richard Nolan	Chief Executive Officer	Sep 10 '24	Sale	10.65	5,000	53,274	120,695	Sep 11 05:17 PM
Richard Nolan Townsend	Director	Sep 10 '24	Proposed Sale	10.79	12,500	134,875		Sep 10 04:39 PM
Townsend Richard Nolan	Chief Executive Officer	Aug 12 '24	Option Exercise	2.33	5,000	11,650	125,695	Aug 13 06:34 PM
Townsend Richard Nolan	Chief Executive Officer	Aug 12 '24	Sale	11.53	5,000	57,634	120,695	Aug 13 06:34 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 10 '24	Option Exercise	2.33	5,000	11,650	175,695	Jul 12 04:55 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 11 '24	Sale	17.07	28,031	478,409	120,695	Jul 12 04:55 PM
Townsend Richard Nolan	Chief Executive Officer	Jul 10 '24	Sale	16.50	26,969	444,979	148,726	Jul 12 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXEO

Lexeo Therapeutics Inc

Upgrade your FINVIZ experience